1. Scrip
  2. >>Business

Novo Nordisk Already Plans A 'Next Generation' Oral Semaglutide - CEO

 
• By Sten Stovall

Planned next generation of oral semaglutide 'is in the early research stage', Lars Fruergaard Jorgensen tells Scrip.

Anatomy
Oral Semaglutide Will Be Aimed At Diabetes, Obesity And Fatty Liver • Source: Shutterstock

Novo Nordisk AS is studying a more powerful 'next-generation' version of its investigative oral GLP-1 semaglutide currently in pivotal trials for type-2 diabetes, and hopes to eventually expand that potential drug's therapeutic scope to include obesity and liver disease, the company's CEO told Scrip in an interview.

Novo Nordisk believes that its investigative oral drug semaglutide – an adapted version of its drug liraglutide - can help type 2 diabetes patients to lower their blood sugar, substantially...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.